The state of Maryland currently has 99 active clinical trials seeking participants for Lung Cancer research studies. These trials are conducted in various cities, including Baltimore, Bethesda, Rockville and Annapolis.
Project PEER: Understanding the Lung Cancer Patient ExperiEnce in the Real-World Setting
Recruiting
LUNGevity Foundation, a non-profit lung cancer organization, wants to learn about living with lung cancer from the point of view of people with lung cancer and their family and friends who provide care. To do this, we have an online study designed to better understand how treatments people living with lung cancer receive impact their quality of life. Participants will complete surveys once a month for 12 months. What does participation involve? Emailing the study team to learn more and get acc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: LUNGevity Foundation, Bethesda, Maryland
Conditions: Lung Cancer Patients, Caregivers
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Recruiting
This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells. This study will have a dose escalation portion (1A) to evaluate maximum tolerated dose (MTD) and/or maximum administered dose (MAD), the safety and tolerability of AG01treatment before the dose expansio... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2022
Locations: University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
PEN-866 in Patients With Advanced Solid Malignancies
Recruiting
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2022
Locations: National Institutes of Health / National Cancer Institute, Bethesda, Maryland
Conditions: Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma